NO317097B1 - N-benzyl-3-indenylacetamidderivater for behandling av neoplasi - Google Patents

N-benzyl-3-indenylacetamidderivater for behandling av neoplasi Download PDF

Info

Publication number
NO317097B1
NO317097B1 NO20002972A NO20002972A NO317097B1 NO 317097 B1 NO317097 B1 NO 317097B1 NO 20002972 A NO20002972 A NO 20002972A NO 20002972 A NO20002972 A NO 20002972A NO 317097 B1 NO317097 B1 NO 317097B1
Authority
NO
Norway
Prior art keywords
group
hydrogen
alkyl
fluoro
methyl
Prior art date
Application number
NO20002972A
Other languages
English (en)
Norwegian (no)
Other versions
NO20002972L (no
NO20002972D0 (no
Inventor
Rifat Pamukcu
Gerhard Sperl
Paul Gross
Klaus Brendel
Gary A Piazza
Original Assignee
Univ Arizona
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/989,353 external-priority patent/US5948779A/en
Application filed by Univ Arizona, Osi Pharm Inc filed Critical Univ Arizona
Publication of NO20002972D0 publication Critical patent/NO20002972D0/no
Publication of NO20002972L publication Critical patent/NO20002972L/no
Publication of NO317097B1 publication Critical patent/NO317097B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20002972A 1997-12-12 2000-06-09 N-benzyl-3-indenylacetamidderivater for behandling av neoplasi NO317097B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/989,353 US5948779A (en) 1997-12-12 1997-12-12 Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
US09/206,245 US6066634A (en) 1997-12-12 1998-12-07 Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia
PCT/GB1998/003712 WO1999031065A1 (en) 1997-12-12 1998-12-11 N-benzyl-3-indenylacetamides derivatives for treating neoplasia

Publications (3)

Publication Number Publication Date
NO20002972D0 NO20002972D0 (no) 2000-06-09
NO20002972L NO20002972L (no) 2000-08-09
NO317097B1 true NO317097B1 (no) 2004-08-09

Family

ID=26901185

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20002972A NO317097B1 (no) 1997-12-12 2000-06-09 N-benzyl-3-indenylacetamidderivater for behandling av neoplasi

Country Status (18)

Country Link
US (3) US6166053A (cs)
EP (1) EP1044187B1 (cs)
JP (1) JP4307719B2 (cs)
CN (1) CN100436418C (cs)
AT (1) ATE257152T1 (cs)
AU (1) AU752072B2 (cs)
BR (1) BR9813540A (cs)
CA (1) CA2314339C (cs)
CZ (1) CZ298826B6 (cs)
DE (1) DE69820908T2 (cs)
ES (1) ES2212383T3 (cs)
HU (1) HU227153B1 (cs)
IL (1) IL136603A0 (cs)
NO (1) NO317097B1 (cs)
NZ (1) NZ504958A (cs)
PL (1) PL196936B1 (cs)
TR (1) TR200001687T2 (cs)
WO (1) WO1999031065A1 (cs)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
DE10058663A1 (de) * 2000-11-25 2002-05-29 Merck Patent Gmbh Verwendung von Thienopyrimidinen
WO2002067936A1 (en) * 2001-02-21 2002-09-06 Cell Pathways, Inc. Methods for treatment of inflammatory bowel disease
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
US20030073711A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of scleroderma
US20030073740A1 (en) * 2001-08-23 2003-04-17 Whitehead Clark M. Methods for treatment of lupus erythematosus
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
CN100398522C (zh) * 2003-08-20 2008-07-02 Irm责任有限公司 组织蛋白酶s的抑制剂
US6995622B2 (en) * 2004-01-09 2006-02-07 Robert Bosh Gmbh Frequency and/or phase compensated microelectromechanical oscillator
WO2005120279A2 (en) 2004-06-02 2005-12-22 Merit Diamond Corporation Comfort interior for jewelry and jewelry including that interior
CN1332930C (zh) * 2005-08-05 2007-08-22 中国科学院上海有机化学研究所 制备乙氰菊酯前体的方法
CN101365461B (zh) * 2006-01-04 2013-07-24 南方研究所 舒林酸衍生物、其用途和其制备
WO2009022756A1 (ja) * 2007-08-13 2009-02-19 Katayama Chemical Industries Co., Ltd. 虚血性疾患の診断及び治療
WO2010053910A1 (en) * 2008-11-04 2010-05-14 Wellstat Therapeutics Corporation Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids
IN2012DN01935A (cs) 2009-08-07 2015-08-21 Auckland Uniservices Ltd
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
CN112020354A (zh) 2018-04-26 2020-12-01 Adt制药有限责任公司 抗癌茚类、茚满类、氮杂茚类、氮杂茚满类、药物组合物和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US5948779A (en) * 1997-12-12 1999-09-07 Cell Pathways, Inc. Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes
CA2314339C (en) * 1997-12-12 2009-09-08 Cell Pathways, Inc. N-benzyl-3-indenylacetamide derivatives for treating neoplasia

Also Published As

Publication number Publication date
ES2212383T3 (es) 2004-07-16
US6610854B2 (en) 2003-08-26
CZ298826B6 (cs) 2008-02-20
CA2314339C (en) 2009-09-08
PL196936B1 (pl) 2008-02-29
EP1044187B1 (en) 2004-01-02
CN1281436A (zh) 2001-01-24
NO20002972L (no) 2000-08-09
HUP0100170A1 (hu) 2001-07-30
CN100436418C (zh) 2008-11-26
TR200001687T2 (tr) 2000-10-23
US6426349B1 (en) 2002-07-30
DE69820908T2 (de) 2004-12-23
CA2314339A1 (en) 1999-06-24
NZ504958A (en) 2003-03-28
BR9813540A (pt) 2000-10-10
AU1498199A (en) 1999-07-05
AU752072B2 (en) 2002-09-05
JP4307719B2 (ja) 2009-08-05
EP1044187A1 (en) 2000-10-18
DE69820908D1 (de) 2004-02-05
CZ20002157A3 (cs) 2000-10-11
ATE257152T1 (de) 2004-01-15
HUP0100170A3 (en) 2001-12-28
HU227153B1 (en) 2010-08-30
US6166053A (en) 2000-12-26
IL136603A0 (en) 2001-06-14
JP2002508358A (ja) 2002-03-19
PL341151A1 (en) 2001-03-26
WO1999031065A1 (en) 1999-06-24
US20030009033A1 (en) 2003-01-09
NO20002972D0 (no) 2000-06-09

Similar Documents

Publication Publication Date Title
CA2314339C (en) N-benzyl-3-indenylacetamide derivatives for treating neoplasia
US6066634A (en) Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia
US6211177B1 (en) Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US20200062732A1 (en) Dna-pk inhibitors
TW201127823A (en) Indole based receptor CRTH2 antagonists
TW201022216A (en) Compounds, compositions and methods of using same for modulating uric acid levels
ES2238324T3 (es) Derivados heterocicloalquilsulfonilpirazol como agentes antiinflamatorios/analgesicos.
JP2018002742A (ja) ヒトヒストンメチルトランスフェラーゼｅｚｈ２阻害剤の塩形態
RS57306B1 (sr) Inhibitori dnk-pk
TW200808771A (en) Novel compounds II
CN107635404B (zh) 用于治疗疾病的mct4抑制剂
US6028116A (en) Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia
US6486158B1 (en) [4,5]-fused-3,6-disubstituted-pyridazines with sulfur-containing substituents in position three for the treatment of neoplasia
JPH0753730B2 (ja) イミダゾピラゾール誘導体
WO2013159698A1 (zh) 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN120309588A (zh) 一种具有雄激素受体和组蛋白去乙酰化酶6双重抑制作用的乙内酰硫脲类化合物及其用途
CN110066271A (zh) 吡咯衍生物、其制备方法、药物组合物及应用
HK1030947B (en) N-benzyl-3-indenylacetamides derivatives for treating neoplasia
US20010051651A1 (en) 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees